My NCBISign In
RSS Settings
  • Search:

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination
  • Your browser version may not work well with NCBI's Web applications. More information here...

Results: 1 to 20 of 368

1.

p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer.

Yamashita H, Toyama T, Nishio M, Ando Y, Hamaguchi M, Zhang Z, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer Res. 2006;8(4):R48.PMID: 16869955 [PubMed - indexed for MEDLINE]Related articlesFree article

2.

Phosphorylation of estrogen receptor alpha serine 167 is predictive of response to endocrine therapy and increases postrelapse survival in metastatic breast cancer.

Yamashita H, Nishio M, Kobayashi S, Ando Y, Sugiura H, Zhang Z, Hamaguchi M, Mita K, Fujii Y, Iwase H.

Breast Cancer Res. 2005;7(5):R753-64. Epub 2005 Jul 27.PMID: 16168121 [PubMed - indexed for MEDLINE]Related articlesFree article

3.

Coexistence of HER2 over-expression and p53 protein accumulation is a strong prognostic molecular marker in breast cancer.

Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S, Iwase H.

Breast Cancer Res. 2004;6(1):R24-30. Epub 2003 Nov 7.PMID: 14680497 [PubMed - indexed for MEDLINE]Related articlesFree article

4.

p53 expression status is a significant molecular marker in predicting the time to endocrine therapy failure in recurrent breast cancer: a cohort study.

Kai K, Nishimura R, Arima N, Miyayama H, Iwase H.

Int J Clin Oncol. 2006 Dec;11(6):426-33. Epub 2006 Dec 25.PMID: 17180510 [PubMed - indexed for MEDLINE]Related articles

5.

Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

Archer SG, Eliopoulos A, Spandidos D, Barnes D, Ellis IO, Blamey RW, Nicholson RI, Robertson JF.

Br J Cancer. 1995 Nov;72(5):1259-66.PMID: 7577479 [PubMed - indexed for MEDLINE]Related articlesFree article

6.

p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer.

Berns EM, Klijn JG, van Putten WL, de Witte HH, Look MP, Meijer-van Gelder ME, Willman K, Portengen H, Benraad TJ, Foekens JA.

J Clin Oncol. 1998 Jan;16(1):121-7.PMID: 9440732 [PubMed - indexed for MEDLINE]Related articles

7.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.PMID: 17993229 [PubMed - indexed for MEDLINE]Related articles

8.

Nuclear corepressor 1 expression predicts response to first-line endocrine therapy for breast cancer patients on relapse.

Zhang ZH, Yamashita H, Toyama T, Yamamoto Y, Kawasoe T, Ibusuki M, Tomita S, Sugiura H, Kobayashi S, Fujii Y, Iwase H.

Chin Med J (Engl). 2009 Aug 5;122(15):1764-8.PMID: 19781322 [PubMed - indexed for MEDLINE]Related articlesFree article

9.

Low phosphorylation of estrogen receptor alpha (ERalpha) serine 118 and high phosphorylation of ERalpha serine 167 improve survival in ER-positive breast cancer.

Yamashita H, Nishio M, Toyama T, Sugiura H, Kondo N, Kobayashi S, Fujii Y, Iwase H.

Endocr Relat Cancer. 2008 Sep;15(3):755-63. Epub 2008 Jun 12.PMID: 18550720 [PubMed - indexed for MEDLINE]Related articlesFree article

10.

A divergent role for estrogen receptor-beta in node-positive and node-negative breast cancer classified according to molecular subtypes: an observational prospective study.

Novelli F, Milella M, Melucci E, Di Benedetto A, Sperduti I, Perrone-Donnorso R, Perracchio L, Venturo I, Nisticò C, Fabi A, Buglioni S, Natali PG, Mottolese M.

Breast Cancer Res. 2008;10(5):R74. Epub 2008 Sep 4.PMID: 18771580 [PubMed - indexed for MEDLINE]Related articlesFree article

11.

Activation of PI3K/Akt signaling and hormone resistance in breast cancer.

Tokunaga E, Kimura Y, Mashino K, Oki E, Kataoka A, Ohno S, Morita M, Kakeji Y, Baba H, Maehara Y.

Breast Cancer. 2006;13(2):137-44.PMID: 16755107 [PubMed - indexed for MEDLINE]Related articlesFree article

12.

Stat5 expression predicts response to endocrine therapy and improves survival in estrogen receptor-positive breast cancer.

Yamashita H, Nishio M, Ando Y, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Endocr Relat Cancer. 2006 Sep;13(3):885-93.PMID: 16954437 [PubMed - indexed for MEDLINE]Related articlesFree article

13.

Tumor histology and stage but not p53, Her2-neu or cathepsin-D expression are independent prognostic factors in breast cancer patients.

Korkolis DP, Tsoli E, Fouskakis D, Yiotis J, Koullias GJ, Giannopoulos D, Papalambros E, Nikiteas NI, Spiliopoulou CA, Patsouris E, Asimacopoulos P, Gorgoulis VG.

Anticancer Res. 2004 May-Jun;24(3b):2061-8.PMID: 15274401 [PubMed - indexed for MEDLINE]Related articles

14.

Immunohistochemical evaluation of hormone receptor status for predicting response to endocrine therapy in metastatic breast cancer.

Yamashita H, Yando Y, Nishio M, Zhang Z, Hamaguchi M, Mita K, Kobayashi S, Fujii Y, Iwase H.

Breast Cancer. 2006;13(1):74-83.PMID: 16518065 [PubMed - indexed for MEDLINE]Related articlesFree article

15.

Immunofluorometrically determined p53 accumulation as a prognostic indicator in Italian breast cancer patients.

Levesque MA, Katsaros D, Yu H, Giai M, Genta F, Roagna R, Ponzone R, Massobrio M, Sismondi P, Diamandis EP.

Int J Cancer. 1998 Apr 17;79(2):147-52.PMID: 9583729 [PubMed - indexed for MEDLINE]Related articles

16.

Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients.

Kröger N, Milde-Langosch K, Riethdorf S, Schmoor C, Schumacher M, Zander AR, Löning T.

Clin Cancer Res. 2006 Jan 1;12(1):159-68.PMID: 16397038 [PubMed - indexed for MEDLINE]Related articlesFree article

17.

Association of GATA3, P53, Ki67 status and vascular peritumoral invasion are strongly prognostic in luminal breast cancer.

Jacquemier J, Charafe-Jauffret E, Monville F, Esterni B, Extra JM, Houvenaeghel G, Xerri L, Bertucci F, Birnbaum D.

Breast Cancer Res. 2009;11(2):R23. Epub 2009 Apr 30.PMID: 19405945 [PubMed - indexed for MEDLINE]Related articlesFree article

18.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. Epub 2009 Feb 24.PMID: 19239686 [PubMed - indexed for MEDLINE]Related articlesFree article

19.

Trastuzumab monotherapy versus combination therapy for treating recurrent breast cancer: time to progression and survival.

Nishimura R, Okumura Y, Arima N.

Breast Cancer. 2008;15(1):57-64.PMID: 18224396 [PubMed - indexed for MEDLINE]Related articles

20.

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.

Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, Kim DW, Kim TY, Park IA, Noh DY, Heo DS, Ha SW, Bang YJ.

BMC Cancer. 2007 Apr 12;7:63.PMID: 17430582 [PubMed - indexed for MEDLINE]Related articlesFree article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Filter your results:

Find related data

Recent activity

You are here: NCBI > Literature > PubMed
Write to the Help Desk